Clinical Trial

A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-371153, a PD-L1 Inhibitor, in patients with advanced solid tumors or relapsed/refractory lymphoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-04-18; most recent amendment 2025-01-22.
Status change: Not Yet Recruiting → Recruiting 2025-01-22
Trial Details
NCT Number NCT05341557
Lead Sponsor Betta Pharmaceuticals Co., Ltd.
Conditions Advanced Solid Tumor, Lymphoma, NSCLC, HCC
Enrollment 110 participants
Start Date 2022-08-29
Primary Completion 2026-12 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2025-01-27